References
- Antony-Debre, I., Manchev, V.T., Balayn, N., Bluteau, D., Tomowiak, C., Legrand, C., Langlois, T., Bawa, O., Tosca, L., Tachdjian, G., et al. (2015). Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood 125, 930-940. https://doi.org/10.1182/blood-2014-06-585513
- Beekman, R., Valkhof, M.G., Sanders, M.A., van Strien, P.M., Haanstra, J.R., Broeders, L., Geertsma-Kleinekoort, W.M., Veerman, A.J., Valk, P.J., Verhaak, R.G., et al. (2012). Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 119, 5071-5077. https://doi.org/10.1182/blood-2012-01-406116
- Bellissimo, D.C. and Speck, N.A. (2017). RUNX1 mutations in inherited and sporadic leukemia. Front. Cell Dev. Biol. 5, 111. https://doi.org/10.3389/fcell.2017.00111
- Cai, X., Gaudet, J.J., Mangan, J.K., Chen, M.J., De Obaldia, M.E., Oo, Z., Ernst, P., and Speck, N.A. (2011). Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS One 6, e28430. https://doi.org/10.1371/journal.pone.0028430
- Chen, C.Y., Lin, L.I., Tang, J.L., Ko, B.S., Tsay, W., Chou, W.C., Yao, M., Wu, S.J., Tseng, M.H., and Tien, H.F. (2007). RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br. J. Haematol. 139, 405-414. https://doi.org/10.1111/j.1365-2141.2007.06811.x
- Chin, D.W., Watanabe-Okochi, N., Wang, C.Q., Tergaonkar, V., and Osato, M. (2015). Mouse models for core binding factor leukemia. Leukemia 29, 1970-1980. https://doi.org/10.1038/leu.2015.181
- Christiansen, D.H., Andersen, M.K., and Pedersen-Bjergaard, J. (2004). Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104, 1474-1481.
- Connelly, J.P., Kwon, E.M., Gao, Y., Trivedi, N.S., Elkahloun, A.G., Horwitz, M.S., Cheng, L., and Liu, P.P. (2014). Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. Blood 124, 1926-1930.
- Dale, D.C., Bonilla, M.A., Davis, M.W., Nakanishi, A.M., Hammond, W.P., Kurtzberg, J., Wang, W., Jakubowski, A., Winton, E., Lalezari, P., et al. (1993). A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81, 2496-2502. https://doi.org/10.1182/blood.V81.10.2496.2496
- Gaidzik, V.I., Bullinger, L., Schlenk, R.F., Zimmermann, A.S., Rock, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011). RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J. Clin. Oncol. 29, 1364-1372. https://doi.org/10.1200/JCO.2010.30.7926
- Germeshausen, M., Ballmaier, M., and Welte, K. (2007). Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 109, 93-99. https://doi.org/10.1182/blood-2006-02-004275
- Goyama, S., Schibler, J., Cunningham, L., Zhang, Y., Rao, Y., Nishimoto, N., Nakagawa, M., Olsson, A., Wunderlich, M., Link, K.A., et al. (2013). Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest. 123, 3876-3888. https://doi.org/10.1172/JCI68557
- Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., and Inaba, T. (2004). High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103, 2316-2324. https://doi.org/10.1182/blood-2003-09-3074
- Harada, H., Harada, Y., Tanaka, H., Kimura, A., and Inaba, T. (2003). Implications of somatic mutations in the AML1 gene in radiationassociated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 101, 673-680. https://doi.org/10.1182/blood-2002-04-1010
- Harada, Y. and Harada, H. (2009). Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J. Cell. Physiol. 220, 16-20. https://doi.org/10.1002/jcp.21769
- Harada, Y., Inoue, D., Ding, Y., Imagawa, J., Doki, N., Matsui, H., Yahata, T., Matsushita, H., Ando, K., Sashida, G., et al. (2013). RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 121, 3434-3446. https://doi.org/10.1182/blood-2012-06-434423
- Hermans, M.H., Antonissen, C., Ward, A.C., Mayen, A.E., Ploemacher, R.E., and Touw, I.P. (1999). Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. J. Exp. Med. 189, 683-692. https://doi.org/10.1084/jem.189.4.683
- Hermans, M.H., Ward, A.C., Antonissen, C., Karis, A., Lowenberg, B., and Touw, I.P. (1998). Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 92, 32-39. https://doi.org/10.1182/blood.V92.1.32.413k42_32_39
- Hino, S., Kishida, S., Michiue, T., Fukui, A., Sakamoto, I., Takada, S., Asashima, M., and Kikuchi, A. (2001). Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol. Cell. Biol. 21, 330-342. https://doi.org/10.1128/MCB.21.1.330-342.2001
- Ko, M., An, J., Bandukwala, H.S., Chavez, L., Aijo, T., Pastor, W.A., Segal, M.F., Li, H., Koh, K.P., Lähdesmäki, H., et al. (2013). Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497, 122-126. https://doi.org/10.1038/nature12052
- Liu, F., Kunter, G., Krem, M.M., Eades, W.C., Cain, J.A., Tomasson, M.H., Hennighausen, L., and Link, D.C. (2008). Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J. Clin. Invest. 118, 946-955. https://doi.org/10.1172/JCI32704
- Mangan, J.K. and Speck, N.A. (2011). RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit. Rev. Oncog. 16, 77-91. https://doi.org/10.1615/CritRevOncog.v16.i1-2.80
- Olofsen, P.A., Fatrai, S., van Strien, P.M.H., Obenauer, J.C., Hoogenboezem, R.M., Erpelinck-Verschueren, C.A.J., Roovers, O., Haferlach, T., Valk, P., Schneider, R.K., et al. (2018). A leukemic progression model of severe congenital neutropenia uncovers a novel mechanism of AML development involving elevated inflammatory responses, mutation of CXXC4 and decreased TET2 levels. Blood 132, 540. https://doi.org/10.1182/blood-2018-99-115914
- Olofsen, P.A., van Strien, P.M.H., Roovers, O., de Looper, H.W.J., Hoogenboezem, R.M., Bosch, D.A., Ghazvini, M., Bindels, E.M.J., de Pater, E.M., and Touw, I.P. (2019). PML plays a key role in severe congenital neutropenia with mutant elane causing neutrophil elastase protein misfolding. Blood 134, 213. https://doi.org/10.1182/blood-2019-122423
- Osato, M. (2004). Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 23, 4284-4296. https://doi.org/10.1038/sj.onc.1207779
- Papapetrou, E.P. (2019). Modeling myeloid malignancies with patientderived iPSCs. Exp. Hematol. 71, 77-84. https://doi.org/10.1016/j.exphem.2018.11.006
- Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J.L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000). High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96, 2862-2869. https://doi.org/10.1182/blood.V96.8.2862
- Quentin, S., Cuccuini, W., Ceccaldi, R., Nibourel, O., Pondarre, C., Pagès, M.P., Vasquez, N., Dubois d'Enghien, C., Larghero, J., Peffault, de Latour, R., et al. (2011). Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 117, e161-e170. https://doi.org/10.1182/blood-2010-09-308726
- Rosenberg, P.S., Alter, B.P., Bolyard, A.A., Bonilla, M.A., Boxer, L.A., Cham, B., Fier, C., Freedman, M., Kannourakis, G., Kinsey, S., et al. (2006). The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107, 4628-4635. https://doi.org/10.1182/blood-2005-11-4370
- Rosenberg, P.S., Zeidler, C., Bolyard, A.A., Alter, B.P., Bonilla, M.A., Boxer, L.A., Dror, Y., Kinsey, S., Link, D.C., Newburger, P.E., et al. (2010). Stable longterm risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br. J. Haematol. 150, 196-199. https://doi.org/10.1111/j.1365-2141.2010.08216.x
- Sakurai, M., Kunimoto, H., Watanabe, N., Fukuchi, Y., Yuasa, S., Yamazaki, S., Nishimura, T., Sadahira, K., Fukuda, K., Okano, H., et al. (2014). Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia 28, 2344-2354. https://doi.org/10.1038/leu.2014.136
- Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C., and Haferlach, T. (2011). RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 117, 2348-2357. https://doi.org/10.1182/blood-2009-11-255976
- Skokowa, J., Dale, D.C., Touw, I.P., Zeidler, C., and Welte, K. (2017). Severe congenital neutropenias. Nat. Rev. Dis. Primers 3, 17032. https://doi.org/10.1038/nrdp.2017.32
- Skokowa, J., Steinemann, D., Katsman-Kuipers, J.E., Zeidler, C., Klimenkova, O., Klimiankou, M., Unalan, M., Kandabarau, S., Makaryan, V., Beekman, R., et al. (2014). Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood 123, 2229-2237. https://doi.org/10.1182/blood-2013-11-538025
- Song, W.J., Sullivan, M.G., Legare, R.D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I.C., Haworth, C., Hock, R., et al. (1999). Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166-175. https://doi.org/10.1038/13793
- Sood, R., Kamikubo, Y., and Liu, P. (2017). Role of RUNX1 in hematological malignancies. Blood 129, 2070-2082. https://doi.org/10.1182/blood-2016-10-687830
- Steensma, D.P., Gibbons, R.J., Mesa, R.A., Tefferi, A., and Higgs, DR. (2005). Somatic point mutations in RUNX1/CBFA2/AML1 are common in highrisk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 74, 47-53. https://doi.org/10.1111/j.1600-0609.2004.00363.x
- Tang, J.L., Hou, H.A., Chen, C.Y., Liu, C.Y., Chou, W.C., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Yao, M., et al. (2009). AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 114, 5352-5361. https://doi.org/10.1182/blood-2009-05-223784
- Touw, I.P. (2015). Game of clones: the genomic evolution of severe congenital neutropenia. Hematology Am. Soc. Hematol. Educ. Program 2015, 1-7. https://doi.org/10.1182/asheducation-2015.1.1
- Watanabe-Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., Nakajima, H., Nosaka, T., Inaba, T., and Kitamura, T. (2008). AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111, 4297-4308. https://doi.org/10.1182/blood-2007-01-068346
- Yzaguirre, A.D., de Bruijn, M.F., and Speck, N.A. (2017). The role of Runx1 in embryonic blood cell formation. Adv. Exp. Med. Biol. 962, 47-64. https://doi.org/10.1007/978-981-10-3233-2_4
- Zhu, Q.S., Xia, L., Mills, G.B., Lowell, C.A., Touw, I.P., and Corey, S.J. (2006). G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood 107, 1847-1856. https://doi.org/10.1182/blood-2005-04-1612